News

PDS Biotechnology Corp (PDSB) – Manufacturing Partner Added to Consortium to Commercialize Coronavirus Vaccine in Latin America

Health
0 min read

Tuesday, February 23, 2021

PDS Biotechnology Corp (PDSB)
Manufacturing Partner Added to Consortium to Commercialize Coronavirus Vaccine in Latin America

PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is primarily engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.

Ahu Demir, Ph. D., Biotechnology Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Adding a partner to manufacture Versamune based coronavirus vaccine. Blanver joined PDS Biotech and Farmacore to commercialize novel Versamune-based T-Cell Inducing COVID-19 vaccine. Based on the agreement, Blanver (based in Sao Paulo) will manufacture, distribute, and commercialize the Versamune-based COVID-19 vaccine in Latin America. Farmacore will continue to lead the regulatory and clinical trial efforts in Brazil as the license holder of Versamune-CoV2-FC (PDS0203) in Latin America. PDS Biotech will continue to contribute scientific expertise and operational support as part of the partnership.

    What is next? The preclinical data is expected in Q2 and the clinical trial is anticipated to commence in H1 2021.  In addition, the consortium is currently in discussions with the Brazilian government to extend preclinical funding to grant clinical studies …



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision. 

Share

Inbox Intel from Channelchek.

Informed investors make more money. And it’s all about timing. Get it when it happens.

By clicking submit you are agreeing to the Terms of Use and Privacy Policy
© 2018-2024 Noble Financial Group, Inc. All Rights Reserved. Channelchek is provided at no cost to be used for information purposes only and not as investment advisement.